Upgrade to SI Premium - Free Trial

Altimmune (ALT)

3.31 +0.02 (0.61%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (11/10/26)

Latest Headlines

Form 4 Altimmune, Inc. For: Aug 13 Filed by: Durso Jerome Benedict August 13, 2026 4:05 PM - SEC Filing Form 10-Q Altimmune, Inc. For: Jun 30 August 12, 2026 4:04 PM - SEC Filing Altimmune, Inc. (ALT) Tops Q2 EPS by 3c August 12, 2026 7:42 AM - StreetInsider Form 8-K Altimmune, Inc. For: Aug 12 August 12, 2026 7:34 AM - SEC Filing Altimmune Announces Second Quarter 2026 Financial Results and Business Update August 12, 2026 7:30 AM - Globe NewsWire Altimmune to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026 August 5, 2026 8:00 AM - Globe NewsWire Form 4 Altimmune, Inc. For: Jul 31 Filed by: WEAVER GREGORY L August 3, 2026 4:06 PM - SEC Filing Form 4 Altimmune, Inc. For: Jul 31 Filed by: Roberts M Scot August 3, 2026 4:06 PM - SEC Filing Altimmune starts Phase 3 trial of pemvidutide for MASH August 3, 2026 8:01 AM - StreetInsider Altimmune Initiates PERFORMA Phase 3 Trial of Pemvidutide in Patients with MASH August 3, 2026 8:00 AM - Globe NewsWire H.C. Wainwright Reiterates Buy Rating on Altimmune (ALT) July 29, 2026 6:53 AM - StreetInsider Form 8-K Altimmune, Inc. For: Jul 28 July 28, 2026 7:04 AM - SEC Filing Altimmune's pemvidutide cuts heavy drinking days in phase 2 trial July 28, 2026 7:00 AM - StreetInsider Altimmune Announces Positive Topline Results from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder July 28, 2026 7:00 AM - Globe NewsWire Leerink Starts Altimmune (ALT) at Outperform June 22, 2026 6:31 AM - StreetInsider Form 8-K Altimmune, Inc. For: Jun 16 June 16, 2026 4:07 PM - SEC Filing Full Article List